Clinical Trial

Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations

Study acronym: ROMEO
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
ROMEO is a Phase III, multicentre, open-label, chronic-dosing extension study evaluating the long-term safety of two dose regimens of tozorakimab in participants with COPD and a history of exacerbations. Eligible participants must have completed one of the predecessor studies.
Protocol Amendment History 2 changes
notable Enrollment reduced: 82 -> 61 participants 2026-07-09
critical Recruitment opened 2026-05-23
Trial Details
NCT Number NCT07566195
Lead Sponsor AstraZeneca
Collaborators: Clinact, Multihealth Group, Contract Research Organization
Conditions Chronic Obstructive Pulmonary Disease, COPD
Enrollment 59 participants
Start Date 2026-05-05
Primary Completion 2028-12-29 (estimated)
Study Completion 2028-12-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-21